BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 13, 2011
View Archived Issues
Sangamo BioSciences provides update on product pipeline
Read More
UCB claims new PI3K inhibitors
Read More
Ortho-McNeil-Janssen Pharma patents new gamma-secretase modulators
Read More
Helix BioPharma submits IND to FDA for first-in-human study of L-DOS47
Read More
New cannabinoid CB1 receptor antagonists presented by sanofi-aventis
Read More
Ferrer claims new melatonin MT1 receptor agonists
Read More
Studies investigate effects of intranasal oxytocin in schizophrenia, depression and autism
Read More
AM-095 displays antifibrotic activity in vivo
Read More
JTT-305 shows bone anabolic effects in vivo
Read More
HPRG-induced downregulation of PlGF shows anticancer potential
Read More
BIND Biosciences begins phase I study of BIND-014 in cancer
Read More
Topica begins enrollment in phase I/IIa luliconazole trial in onychomycosis
Read More
Ablynx reports follow-up data from phase I trial of ALX-0141
Read More
AstraZeneca and SCRI join to develop targeted anticancer agent
Read More
Concert Pharma claims new PDE4 inhibitors and TNF-alpha production suppressors
Read More
Allozyne completes phase Ia trial of AZ-01 for multiple sclerosis
Read More
New inhibitors of HCV NS5A developed at Enanta Pharma
Read More
Omthera reports bioavailability data from ECLIPSE trial of Epanova
Read More
Sumavel DosePro obtains marketing approval in Germany and U.K.
Read More
FDA issues positive feedback for design of phase III Davanat trial in colorectal cancer
Read More
Peregrine Pharma begins phase II bavituximab trial in hepatitis C
Read More
Enrollment begins in phase III trial of sapacitabine as front-line AML therapy
Read More
Antigenics becomes Agenus and expands product portfolio
Read More
BioMarin begins phase I/II trial of BMN-673 in genetically defined cancers
Read More
Curis selects CUDC-907 as development candidate for targeted cancer program
Read More
